Browse > Article
http://dx.doi.org/10.13160/ricns.2017.10.2.85

HQSAR Study on Substituted 1H-Pyrazolo[3,4-b]pyridines Derivatives as FGFR Kinase Antagonists  

Bhujbal, Swapnil P. (Department of Biomedical Sciences, College of Medicine, Chosun University)
Balasubramanian, Pavithra K. (Department of Biomedical Sciences, College of Medicine, Chosun University)
Keretsu, Seketoulie (Department of Biomedical Sciences, College of Medicine, Chosun University)
Cho, Seung Joo (Department of Biomedical Sciences, College of Medicine, Chosun University)
Publication Information
Journal of Integrative Natural Science / v.10, no.2, 2017 , pp. 85-94 More about this Journal
Abstract
Fibroblast growth factor receptor (FGFR) belongs to the family of receptor tyrosine kinase. They play important roles in cell proliferation, differentiation, development, migration, survival, wound healing, haematopoiesis and tumorigenesis. FGFRs are reported to cause several types of cancers in humans which make it an important drug target. In the current study, HQSAR analysis was performed on a series of recently reported 1H-Pyrazolo [3,4-b]pyridine derivatives as FGFR antagonists. The model was developed with Atom (A) and bond (B) connection (C), chirality (Ch), hydrogen (H) and donor/acceptor (DA) parameters and with different set of atom counts to improve the model. A reasonable HQSAR model ($q^2=0.701$, SDEP=0.654, NOC=5, $r^2=0.926$, SEE=0.325, BHL=71) was generated which showed good predictive ability. The contribution map depicted the atom contribution in inhibitory effect. A contribution map for the most active compound (compound 24) indicated that hydrogen and nitrogen atoms in the side chains of ring B as well as hydrogen atoms in the side chain of ring C and the nitrogen atom in the ring D contributed positively to the activity in inhibitory effect whereas, the lowest active compound (compound 04) showed negative contribution to inhibitory effect. Thus results of our study can provide insights in the designing potent and selective FGFR kinase inhibitors.
Keywords
FGFR Kinase; HQSAR; Pyridine Derivatives; FGFR Kinase Inhibitors;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 J. M. Siegfried, M. Farooqui, N. J. Rothenberger, S. Dacic, and L. P. Stabile, "Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer", Oncotarget, Vol. 8, pp. 24063-24076, 2017.
2 E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010.   DOI
3 Y. J. Shi, J. Y. Tsang, Y. B. Ni, S. K. Chan, K. F. Chan and G. M. Tse, "FGFR1 is an adverse outcome indicator for luminal A breast cancers", Oncotarget, Vol. 7, pp. 5063-5073, 2016.   DOI
4 N. Turner and R. Grose, "Fibroblast growth factor signalling: from development to cancer", Nat. Rev. Cancer, Vol. 10, pp. 116-129, 2010.   DOI
5 N. Brooks, E. Kilgour, and P. D. Smith, "Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer", Clin. Cancer Res., Vol. 18, pp. 1855-1862, 2012.   DOI
6 S. Lemieux and M. K. Hadden, "Targeting the fibroblast growth factor receptors for the treatment of cancer", Anti-Cancer Agents Med. Chem., Vol. 13, pp. 748-761, 2013.   DOI
7 R. Porta, R. Borea, A. Coelho, S. Khan, A. Araujo, P. Reclusa, T. Franchina, N. V. D. Steen, P. V. Dam, J. Ferri, R. Sirera, A. Naing, D. Hong, and C. Rolfo, "FGFR a promising druggable target in cancer: Molecular biology and new drugs", Crit. Rev. Oncol. Hematol., Vol. 113, pp. 256-267, 2017.   DOI
8 H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano, "Management of hypertension in angiogenesis inhibitor-treated patients", Ann. Oncol., Vol. 20, pp. 807-815, 2009.   DOI
9 S. Ricciardi, S. Tomao, and F. de Marinis, "Toxicity of targeted therapy in non-small-cell lung cancer management", Clin. Lung Cancer, Vol. 10, pp. 28-35, 2009.   DOI
10 B. Zhao, Y. Li, P. Xu, Y. Dai, C. Luo, Y. Sun, J. Ai, M. Geng, and W. Duan, "Discovery of substituted 1H-Pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors", ACS Med. Chem. Lett., Vol. 7, pp. 629-634, 2016.   DOI
11 M. Clark, R. D. Cramer III, and N. V. Opdenbosch, "Validation of the General Purpose Tripos 5.2 Force Field", J. Comput. Chem., Vol. 10, pp. 982-1012, 1989.   DOI
12 R. Kumar, B. Langstrom, and T. Darreh-Shori, "Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization", Sci. Rep., Vol. 6, p. 31247, 2016.   DOI
13 A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of glycogen synthase kinase 3 inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 40-47, 2015.   DOI
14 A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of quinazoline-based anticancer agents", J. Chosun Natural Sci., Vol. 8, pp. 214-220, 2015.   DOI
15 A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "Comparative molecular field analysis of pyrrolopyrimidinesas LRRK2 kinase inhibitors", J. Chosun Natural Sci., Vol. 9, pp. 1-9, 2016.   DOI
16 P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014.   DOI
17 A. D. Luca, D. Frezzetti, M. Gallo, and N. Normanno, "FGFR-targeted therapeutics for the treatment of breast cancer", Expert Opin. Investig. Drugs, Vol. 26, pp. 303-311, 2017.   DOI
18 I. S. Babina and N. C. Turner, "Advances and challenges in targeting FGFR signalling in cancer", Nat. Rev. Cancer, Vol. 17, pp. 318-332, 2017.   DOI
19 M. Touat, E. Ileana, S. Postel-Vinay, F. Andre, and J. C. Soria, "Targeting FGFR signaling in cancer", Clin. Cancer Res., Vol. 21, pp. 2684-2694, 2015.   DOI
20 K. H. Tiong, L. Y. Mah, and C.-O. Leong, "Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers", Apoptosis, Vol. 18, pp. 1447-1468, 2013.   DOI
21 E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010.   DOI
22 H. Greulich and P. M. Pollock, "Targeting mutant fibroblast growth factor receptors in cancer", Trends Mol. Med., Vol. 17, pp. 283-292, 2013.
23 H. K. Ho, A. H. Yeo, T. S. Kang, and B. T. Chua, "Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations", Drug Discov. Today, Vol. 9, pp. 51-62, 2014.